Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2013
ERCC1 and RRM1: ready for prime time?
Benjamin Besse, Ken A Olaussen, Jean-Charles Soria
Nature Reviews. Clinical Oncology
|
August 16, 2018
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Gonzalo Recondo, Francesco Facchinetti, Ken A Olaussen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2019
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Francesco Facchinetti, Antoine Hollebecque, Rastislav Bahleda, et al.
Nature Reviews. Clinical Oncology
|
February 15, 2012
The potential of exploiting DNA-repair defects for optimizing lung cancer treatment
Sophie Postel-Vinay, Elsa Vanhecke, Ken A Olaussen, et al.
DNA Repair
|
February 27, 2018
A novel antibody-based approach to detect the functional ERCC1-202 isoform
Mei-Shiue Kuo, Julien Adam, Nicolas Dorvault, et al.
Cell Cycle (Georgetown, Tex.)
|
January 31, 2016
Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance
Tony Sourisseau, Carole Helissey, Céline Lefebvre, et al.
Cell Cycle (Georgetown, Tex.)
|
February 23, 2013
Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer
Judith Michels, Ilio Vitale, Laura Senovilla, et al.
Plos One
|
December 27, 2007
Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway
Ilio Vitale, Lorenzo Galluzzi, Sonia Vivet, et al.
Cancer Biomarkers : Section a of Disease Markers
|
November 2, 2016
MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer
Julien Adam, Tony Sourisseau, Ken A Olaussen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2010
MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer
Nermine S Kamal, Jean-Charles Soria, Jean Mendiboure, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2013
ERCC1 and RRM1: ready for prime time?
Benjamin Besse, Ken A Olaussen, Jean-Charles Soria
Nature Reviews. Clinical Oncology
|
August 16, 2018
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Gonzalo Recondo, Francesco Facchinetti, Ken A Olaussen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2019
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Francesco Facchinetti, Antoine Hollebecque, Rastislav Bahleda, et al.
Nature Reviews. Clinical Oncology
|
February 15, 2012
The potential of exploiting DNA-repair defects for optimizing lung cancer treatment
Sophie Postel-Vinay, Elsa Vanhecke, Ken A Olaussen, et al.
DNA Repair
|
February 27, 2018
A novel antibody-based approach to detect the functional ERCC1-202 isoform
Mei-Shiue Kuo, Julien Adam, Nicolas Dorvault, et al.
Cell Cycle (Georgetown, Tex.)
|
January 31, 2016
Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance
Tony Sourisseau, Carole Helissey, Céline Lefebvre, et al.
Cell Cycle (Georgetown, Tex.)
|
February 23, 2013
Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer
Judith Michels, Ilio Vitale, Laura Senovilla, et al.
Plos One
|
December 27, 2007
Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway
Ilio Vitale, Lorenzo Galluzzi, Sonia Vivet, et al.
Cancer Biomarkers : Section a of Disease Markers
|
November 2, 2016
MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer
Julien Adam, Tony Sourisseau, Ken A Olaussen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2010
MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer
Nermine S Kamal, Jean-Charles Soria, Jean Mendiboure, et al.
Page
of 3